ClearPoint Neuro Secures 10-Year Partnership to Advance Brain Drug Delivery
Seoul, Wednesday, 27 May 2026.
Following a successful trial, ClearPoint Neuro’s decade-long partnership with Sungkyunkwan University will utilize ultrasound technology to safely deliver complex medications across the notoriously impenetrable blood-brain barrier.
Breaking the Barrier: A Technological Milestone
On May 26 and May 27, 2026, ClearPoint Neuro, Inc. (NASDAQ: CLPT) formally announced its strategic entry into the focused ultrasound market [1]. This announcement follows the successful intravenous delivery of FITC Dextran and Evans Blue tracers across the blood-brain barrier within a preclinical model [1]. The milestone represents the culmination of a nearly four-year collaborative effort with the SONOCARELAB at Sungkyunkwan University, situated on the Natural Science Campus in Suwon, South Korea [1]. By integrating prototype focused ultrasound hardware with ClearPoint’s established neuro-navigation software and robotics—leveraging a foundation of development that traces back to approximately 2011—the company has demonstrated a viable method for targeted large molecule drug delivery [1].
Strategic Shifts from MRI to the Operating Room
A pivotal element of ClearPoint Neuro’s commercial strategy involves shifting the deployment environment of its technologies. Historically reliant on magnetic resonance imaging (MRI) settings, the company plans to deploy its new focused ultrasound prototype and robotic navigation platform within traditional operating rooms [1]. This transition will utilize intraoperative computed tomography (iCT) imaging, effectively removing the procedure from the highly specialized and often cost-prohibitive MRI environment [1]. The objective is to facilitate scalable, cost-effective, and consistent targeted drug delivery to widespread regions of the brain [1].
Global Expansion and the Drug Delivery Ecosystem
The formalization of the 10-year development partnership with Sungkyunkwan University solidifies ClearPoint Neuro’s international footprint and research capabilities [1]. Professor Jinhyoung Park of Sungkyunkwan University highlighted that the collaboration has already proven the viability of integrating “advanced therapeutic ultrasound technologies with image-guided robotic neurointervention platforms in large preclinical subjects” [1]. This long-term agreement will dictate the scope, duration, and specific clinical outcomes of developing future focused ultrasound technologies [1].